Advertisement
BMY or MRK or REGN
Which Stock Would AI Choose? Bristol-Myers Squibb (BMY) vs. Merck & Co. (MRK) vs. Regeneron Pharmaceuticals (REGN) Stock Comparison
Key Takeaways
- BMY trades at a forward P/E of around 9.5x with a 4.3% dividend yield, supported by YTD gains of over 11% amid growth portfolio momentum offsetting legacy declines.
- MRK shows strong oncology and vaccine sales, with 2026 revenue guidance of $63.5-65.5 billion, though Keytruda patent concerns loom in 2028; YTD up nearly 10%.
- REGN benefits from Dupixent's robust growth and Eylea HD uptake, but faces Eylea biosimilar erosion; YTD performance mixed around flat to positive amid pipeline expansions.
- Recent weeks highlight pipeline catalysts: BMY deep late-stage assets, MRK Keytruda combos, REGN label expansions for Dupixent and Eylea HD.
- All three exhibit relative stability in biotech/pharma sector, with BMY and MRK offering higher yields versus REGN's growth focus.
- Market positioning favors diversified large-caps like BMY and MRK over biotech pure-play REGN amid volatility.
Introduction
This stock comparison examines BMY, a diversified biopharma leader in oncology and immunology; MRK, known for its oncology powerhouse Keytruda and vaccines; and REGN, focused on innovative antibodies like Dupixent and Eylea. These companies operate in the competitive biopharmaceutical sector, where pipeline progress, patent dynamics, and revenue diversification drive relative performance. Traders seeking momentum plays and long-term investors eyeing dividends or growth catalysts will find value in analyzing their recent market activity, valuations, and strategic positioning amid evolving healthcare demands.
BMY Overview and Recent Performance
Bristol-Myers Squibb (BMY) is a global biopharmaceutical firm emphasizing oncology, hematology, immunology, and cardiovascular therapies, with blockbusters like Eliquis and Opdivo anchoring revenues. In recent market activity, shares have risen over 11% YTD, trading around $59 with a market cap near $120 billion and forward P/E of 9.5x, bolstered by a 4.3% dividend yield. Growth portfolio sales grew 17% in 2025, offsetting 15% legacy declines from generics, leading to flat overall revenues of $48.2 billion. Sentiment has improved on 2026 guidance of $46-47.5 billion revenue despite further legacy erosion of 12-16%, driven by pipeline readouts for milvexian, admilparant, and CELMoDs like iberdomide. Positive interim data from the SUCCESSOR-2 study in multiple myeloma further supports optimism, positioning BMY for transition beyond patent cliffs.
MRK Overview and Recent Performance
Merck & Co. (MRK), trading as NYSE:MRK outside the U.S., specializes in oncology via Keytruda, vaccines, and animal health. Shares hover near $116 with a $286 billion market cap, PE around 16x, and 2.9% yield; YTD gains approach 10%. Recent performance reflects oncology and vaccine strength, with 2025 revenues up 1% to $64.2 billion and 2026 guidance at $63.5-65.5 billion. Keytruda drives growth, targeting $70 billion commercial potential post-2028 exclusivity loss, aided by combos like KEYTRUDA plus WELIREG in renal cell carcinoma and subcutaneous QLEX formulation. Restructuring into oncology and non-oncology units underscores preparation for patent challenges, while pipeline wins in bladder, ovarian cancers, HIV, and RSV bolster sentiment amid stable momentum.
REGN Overview and Recent Performance
Regeneron Pharmaceuticals (REGN) develops monoclonal antibodies and genetics-based therapies, led by Eylea family and Dupixent collaboration with Sanofi. Shares trade around $746 with an $83 billion market cap and PE near 19x, showing modest YTD stability. Recent weeks feature Dupixent's global sales surge to $17.8 billion in 2023 (32% YoY) and ongoing expansions in COPD, CSU, bullous pemphigoid; Eylea HD U.S. sales up 66% quarterly despite standard Eylea declines from biosimilars. Total ophthalmology revenues dipped but HD uptake and RVO approval in Europe mitigate erosion. Pipeline progress includes Lynozyfic approval in myeloma, Libtayo expansions, and upcoming data in obesity, neurology; 2026 biosimilar pressures on Eylea expected, offset by Dupixent's breadth serving 1.4 million patients.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the top-performing bots from a library of 351 AI Trading Bots that analyze thousands of tickers across diverse strategies and timeframes. This curated section highlights 25 bots best suited to current market conditions, featuring annualized returns from +17% to over +200%, win rates of 53-95%, and profit factors up to 25.8. Examples include a USAR/SMR/CIFR bot at +210% annualized (76% win rate) and semiconductors-focused agents exceeding +100% with 70%+ wins. These bots employ varied styles—from swing trading 2x/3x ETFs to pattern recognition in energy, aerospace, and small-caps—delivering profit-to-drawdown ratios up to 22.6. Traders can explore and subscribe to these high-conviction signals for potential edge in volatile environments. Visit Trending AI Robots to review live performance and align with your strategy.
Head-to-Head Comparison
BMY, MRK, and REGN share biopharma exposure but diverge in models: BMY and MRK offer broad diversification across oncology/immunology with large-cap stability ($120B+ caps), while REGN leans biotech-focused on antibodies. Growth drivers contrast—MRK's Keytruda ($35B+ peak) faces 2028 cliffs but boasts $70B pipeline potential; BMY transitions via CELMoDs/ bispecifics amid legacy erosion; REGN rides Dupixent expansions versus Eylea biosimilars. Recent momentum favors BMY (11%+ YTD), with MRK stable and REGN flat. Risks include patents for all, but BMY/MRK higher yields (4.3%/2.9%) versus REGN's 0.5%; valuations cheapest for BMY at 9.5x forward, REGN priciest at 19x on growth. Sector tailwinds in oncology/inflammation favor contrasts, with trade-offs in stability versus upside.
Tickeron AI Verdict
Tickeron’s AI currently leans toward BMY based on trend consistency from growth portfolio resilience, attractive valuation (forward P/E ~9.5x), high yield (4.3%), and multiple 2026 catalysts like milvexian data amid manageable legacy declines. MRK follows closely with Keytruda stability and pipeline depth, while REGN offers probabilistic upside from Dupixent but higher biosimilar risks. Observable factors suggest BMY's relative positioning provides the strongest risk-reward in current conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMY’s FA Score shows that 2 FA rating(s) are green whileMRK’s FA Score has 4 green FA rating(s), and REGN’s FA Score reflects 2 green FA rating(s).
- BMY’s FA Score: 2 green, 3 red.
- MRK’s FA Score: 4 green, 1 red.
- REGN’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMY’s TA Score shows that 6 TA indicator(s) are bullish while MRK’s TA Score has 4 bullish TA indicator(s), and REGN’s TA Score reflects 2 bullish TA indicator(s).
- BMY’s TA Score: 6 bullish, 4 bearish.
- MRK’s TA Score: 4 bullish, 4 bearish.
- REGN’s TA Score: 2 bullish, 7 bearish.
Price Growth
BMY (@Pharmaceuticals: Major) experienced а +2.64% price change this week, while MRK (@Pharmaceuticals: Major) price change was -1.94% , and REGN (@Biotechnology) price fluctuated +0.23% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.21%. For the same industry, the average monthly price growth was +2.48%, and the average quarterly price growth was +7.89%.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.61%. For the same industry, the average monthly price growth was +9.02%, and the average quarterly price growth was +11.47%.
Reported Earning Dates
BMY is expected to report earnings on Apr 30, 2026.
MRK is expected to report earnings on Apr 30, 2026.
REGN is expected to report earnings on Apr 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.21% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (+7.61% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| BMY | MRK | REGN | |
| Capitalization | 123B | 294B | 79.4B |
| EBITDA | 15.2B | 28.3B | 5.82B |
| Gain YTD | 14.032 | 13.958 | -2.643 |
| P/E Ratio | 17.39 | 16.36 | 18.09 |
| Revenue | 48.2B | 65B | 14.3B |
| Total Cash | N/A | N/A | 8.61B |
| Total Debt | 47.1B | 49.3B | 2.71B |
BMY | MRK | REGN | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 9 | 55 | 63 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 41 Fair valued | 21 Undervalued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 81 | 48 | 75 | |
SMR RATING 1..100 | 23 | 25 | 54 | |
PRICE GROWTH RATING 1..100 | 21 | 16 | 26 | |
P/E GROWTH RATING 1..100 | 66 | 28 | 40 | |
SEASONALITY SCORE 1..100 | n/a | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
REGN's Valuation (3) in the Biotechnology industry is in the same range as MRK (21) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for BMY (41) in the Pharmaceuticals Major industry. This means that REGN's stock grew similarly to MRK’s and somewhat faster than BMY’s over the last 12 months.
MRK's Profit vs Risk Rating (48) in the Pharmaceuticals Major industry is in the same range as REGN (75) in the Biotechnology industry, and is somewhat better than the same rating for BMY (81) in the Pharmaceuticals Major industry. This means that MRK's stock grew similarly to REGN’s and somewhat faster than BMY’s over the last 12 months.
BMY's SMR Rating (23) in the Pharmaceuticals Major industry is in the same range as MRK (25) in the Pharmaceuticals Major industry, and is in the same range as REGN (54) in the Biotechnology industry. This means that BMY's stock grew similarly to MRK’s and similarly to REGN’s over the last 12 months.
MRK's Price Growth Rating (16) in the Pharmaceuticals Major industry is in the same range as BMY (21) in the Pharmaceuticals Major industry, and is in the same range as REGN (26) in the Biotechnology industry. This means that MRK's stock grew similarly to BMY’s and similarly to REGN’s over the last 12 months.
MRK's P/E Growth Rating (28) in the Pharmaceuticals Major industry is in the same range as REGN (40) in the Biotechnology industry, and is somewhat better than the same rating for BMY (66) in the Pharmaceuticals Major industry. This means that MRK's stock grew similarly to REGN’s and somewhat faster than BMY’s over the last 12 months.
| BMY | MRK | REGN | |
|---|---|---|---|
| RSI ODDS (%) | 3 days ago 42% | N/A | N/A |
| Stochastic ODDS (%) | 3 days ago 48% | 3 days ago 62% | 3 days ago 75% |
| Momentum ODDS (%) | 3 days ago 45% | 3 days ago 47% | 3 days ago 52% |
| MACD ODDS (%) | 3 days ago 55% | 3 days ago 59% | 3 days ago 49% |
| TrendWeek ODDS (%) | 3 days ago 52% | 3 days ago 48% | 3 days ago 66% |
| TrendMonth ODDS (%) | 3 days ago 54% | 3 days ago 52% | 3 days ago 60% |
| Advances ODDS (%) | 3 days ago 54% | 18 days ago 52% | 19 days ago 64% |
| Declines ODDS (%) | 7 days ago 53% | 4 days ago 50% | 4 days ago 51% |
| BollingerBands ODDS (%) | 3 days ago 48% | 3 days ago 69% | 3 days ago 49% |
| Aroon ODDS (%) | 3 days ago 55% | 3 days ago 54% | 3 days ago 70% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SCHX | 27.99 | 0.34 | +1.23% |
| Schwab US Large-Cap ETF™ | |||
| CA | 25.05 | 0.10 | +0.41% |
| Xtrackers California Municipal Bond ETF | |||
| BSMW | 25.14 | 0.07 | +0.27% |
| Invesco BulletShares 2032 Muncpl Bd ETF | |||
| LVLN | 24.71 | 0.06 | +0.24% |
| State Street SPDR S&P Leveraged Ln ETF | |||
| PHK | 4.67 | -0.03 | -0.64% |
| PIMCO High Income Fund | |||
BMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To BMY | 1D Price Change % | ||
|---|---|---|---|---|
| BMY | 100% | +2.05% | ||
| PFE - BMY | 63% Loosely correlated | +1.25% | ||
| MRK - BMY | 60% Loosely correlated | +3.13% | ||
| AMGN - BMY | 58% Loosely correlated | +1.69% | ||
| BIIB - BMY | 54% Loosely correlated | +0.76% | ||
| ABBV - BMY | 54% Loosely correlated | -0.29% | ||
More | ||||